Anindyajati -

Ms. Anindyajati -


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
ADAngga Dwiartama
Angga Dwiartama
WNWahyu Fadzilla Nirbayati
Wahyu Fadzilla Nirbayati
EGErnawati Arifin Giri-Rachman
Ernawati Arifin Giri-Rachman
WNWardono Niloperbowo
Wardono Niloperbowo
MTMarselina Irasonia Tan
Marselina Irasonia Tan
A-Anindyajati -
Anindyajati -
Hepatitis B has been one of the most prevalent infectious diseases in the world and specifically in Indonesia. Although the total conversion of hepatitis B virus (HBV) to chronic disease in Indonesia was reduced by 50%, the total number of hepatitis B cases increased by 2.5 times in 2021. Ineffective HBV immunization program in Indonesia prior to 1997 was addressed by the Ministry of Health through a more comprehensive HBV control, which, among others, involved Health Promotion to increase people’s knowledge and awareness towards hepatitis B infection prevention. In this regard, this study aims to identify the level of knowledge, attitude, and practice/behavior of the Indonesian population towards hepatitis B infection prevention and their willingness for screening, particularly in areas with high prevalence of hepatitis B. This study used a quantitative approach in looking at correlations between this set of knowledge, attitude, and practice, mainly by using Structural Equation Model (SEM) and SmartPLS 3.3.3 toolkit in SPSS. Through an analysis of online questionnaire results from over 400 respondents in four provinces (DKI Jakarta, West Java, DI Yogyakarta, and South Sulawesi), this study shows that respondents have a very high level of knowledge about hepatitis B; high level of positive attitude; and very high level of positive practice towards hepatitis B infection prevention. However, we also noticed some dissonances between the key aspects, namely that knowledge on hepatitis B correlates negatively with the behavior of the respondents and that the behavior also correlates negatively with their willingness for screening. In conclusion, we suggest that factors such as socio-economic context and prior informed knowledge on hepatitis B be considered to build a better strategy of Health Promotion and hepatitis B diagnostic screening among the population.

22 June 2024 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
Nurul JummahNurul Jummah
Nurul Jummah
SSSatrialdi Satrialdi
Satrialdi Satrialdi
AAAnita Artarini
Anita Artarini
A-Anindyajati -
Anindyajati -
DMDiky Mudhakir
Diky Mudhakir
Purpose: This study evaluated whether a nanostructured lipid carrier (NLC) delivery system could safely and accurately deliver nucleic acids to the cell nucleus using the enhanced green fluorescent protein (EGFP)-C1 plasmid model. Methods: The NLC was formulated using the emulsification method and equipped for cationic lipid-mediated transfection with 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), which interacts electrostatically with nucleic acid. The NLC attributes, including size, polydispersity index, and zeta potential, were assessed by dynamic light scattering (DLS). The morphological structure was analyzed using transmission electron microscopy. Entrapment efficiency was evaluated by a direct method. Cellular uptake mechanisms of pEGFP-C1-NLC and the ability of pEGFP-C1 to penetrate the nucleus of TM4 cells to express EGFP were observed using confocal microscopy. Results: pEGFP-C1-NLC exhibited particle sizes in the range 56-88 nm with a particle charge range of -6.0 to+1.3 mV. The polydispersity index<0.5 showed good size uniformity, and entrapment efficiency of pEGFP-C1in the NLC was 92.06±2.295%. The NLC formulation was internalized predominantly via caveolae-mediated endocytosis, as indicated by EGFP expression following successful delivery of pEGFP by the NLC into the cells. Conclusion: NLC formulation could deliver genetic material to the nucleus and could be considered a gene therapy candidate for spermatogenesis.

11 January 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Nurul JummahNurul Jummah
Nurul Jummah
HKHanifa Syifa Kamila
Hanifa Syifa Kamila
SSSatrialdi Satrialdi
Satrialdi Satrialdi
AAAnita Artarini
Anita Artarini
ESEbrahim Saad Sadaqa
Ebrahim Saad Sadaqa
DMDiky Mudhakir
Diky Mudhakir
Background: Diabetic nephropathy (DN) is largely driven by transforming growth factor-β1 (TGF-β1)-mediated fibrosis. Clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) ribonucleoprotein (RNP) complexes offer precise gene disruption, yet effective non-viral delivery remains a challenge. This study developed cationic lipid-based hybrid nanostructured lipid carriers (NLCs) for intracellular delivery of TGFB1-targeting RNP as an early-stage platform for DN gene modulation. Methods: A single-guide RNA (sgRNA) targeting human TGFB1 was assembled with Cas9 protein (1:1 and 1:2 molar ratios). Hybrid NLCs comprising squalene, glyceryl trimyristate, and the cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) were formulated via optimized emulsification–sonication to achieve sub-100 nm particles. Physicochemical properties, including polydispersity index (PDI), were assessed via dynamic light scattering (DLS), while silencing efficacy in HEK293T cells was quantified using quantitative reverse transcription PCR (RT-qPCR) and enzyme-linked immunosorbent assay (ELISA). Results: Optimized NLCs achieved hydrodynamic diameters of 65–99 nm (PDI < 0.5) with successful RNP complexation. The 1:2 Cas9:sgRNA formulation produced the strongest gene-editing response, reducing TGFB1 mRNA by 67% (p < 0.01) compared with 39% for the 1:1 ratio. This translated to a significant reduction in TGF-β1 protein (p < 0.05) within 24 h. Conclusions: DOTAP-based hybrid NLCs enable efficient delivery of CRISPR–Cas9 RNP and achieve significant suppression of TGFB1 expression at both transcriptional and protein levels. These findings establish a promising non-viral platform for upstream modulation of profibrotic signaling in DN and support further evaluation in kidney-derived cells and in vivo renal models.